Keywords: AstraZeneca, Heptares, GPCR, CNS, Pain, Cardiovascular, Inflammatory diseases

AstraZeneca gains rights to Heptares GPCR drug for $6.25 million upfront

Article | 31 May 2011

Print This

Anglo-Swedish drug major AstraZeneca (LSE: AZN) revealed this morning that it has entered a four-year collaboration with fellow UK-based drug ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in